simendan has been researched along with Cardiac Diseases in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, WT; Lei, YY; Lin, XF; Liu, DH; Liu, YY; Ning, YL; Xian, SX; Yang, ZQ | 1 |
| Cheng, Q; Guo, J; Zhang, X; Zhu, Y | 1 |
| Burton, F; Dietrichs, ES; Ghasemi, M; Selli, AL; Smith, G; Watters, T | 1 |
| Al-Beidh, F; Antcliffe, DB; Ashby, D; Cross, M; Gordon, AC; Mason, AJ; McAuley, DF; O'Dea, K; Orme, RML; Perkins, GD; Santhakumaran, S; Singer, M; Ward, JK | 1 |
| Bettex, D; Bouchez, S; Cholley, B; Guarracino, F; Heringlake, M; Kivikko, M; Lomivorotov, VV; Pollesello, P; Rajek, A | 1 |
| Gao, X; Hu, C; Liu, P; Sun, L; Wang, Y; Xu, Z; Zhang, Y; Zhou, X | 1 |
| Huo, JH; Luo, X; Qiang, H; Wang, ZQ | 1 |
| Andreadou, I; Chavdoula, E; Cokkinos, DV; Davos, CH; Efentakis, P; Farmakis, D; Gioti, K; Iliodromitis, EK; Klinakis, A; Kostomitsopoulos, N; Papapetropoulos, A; Sanoudou, D; Sigala, F; Suter, T; Tasouli, A; Tenta, R; Varela, A; Wenzel, P | 1 |
| Harjola, VP; Kivikko, M; Parissis, J; Pollesello, P | 1 |
| Bignami, E; Biondi-Zoccai, G; Bruno, G; Corno, L; Gerli, C; Landoni, G; Mizzi, A; Zambon, M; Zangrillo, A | 1 |
| Boboshko, VA; Cherniavskiy, AM; Karaskov, AM; Kornilov, IA; Lomivorotov, VN; Lomivorotov, VV | 1 |
| Graudins, A; Kalam, Y | 1 |
| Cromheecke, S; De Hert, SG; Lorsomradee, S; Van der Linden, PJ | 1 |
5 review(s) available for simendan and Cardiac Diseases
| Article | Year |
|---|---|
Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis.
Topics: Disease-Free Survival; Dobutamine; Heart Diseases; Lactic Acid; Sepsis; Simendan; Stroke Volume; Survival Rate | 2021 |
Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.
Topics: Adult; Cardiac Surgical Procedures; Global Health; Heart Diseases; Humans; Incidence; Length of Stay; Phosphodiesterase 3 Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Simendan; Survival Rate | 2018 |
Perioperative Use of Levosimendan Improves Clinical Outcomes in Patients After Cardiac Surgery: A Systematic Review and Meta-Analysis.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Cardiovascular Agents; Drug Administration Schedule; Heart Diseases; Humans; Incidence; Intensive Care Units; Length of Stay; Perioperative Care; Renal Replacement Therapy; Respiration, Artificial; Risk Factors; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Levosimendan meta-analyses: Is there a pattern in the effect on mortality?
Topics: Cardiotonic Agents; Cause of Death; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Heart Diseases; Humans; Hydrazones; Meta-Analysis as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2016 |
Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials.
Topics: Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass, Off-Pump; Heart Diseases; Humans; Hydrazones; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2010 |
3 trial(s) available for simendan and Cardiac Diseases
| Article | Year |
|---|---|
Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
Topics: Aged; Biomarkers; Chemokine CCL2; Double-Blind Method; Female; Heart Diseases; HSP90 Heat-Shock Proteins; Humans; Intensive Care Units; Interleukin-10; Interleukin-6; Interleukin-8; Male; Middle Aged; Natriuretic Peptide, Brain; Organ Dysfunction Scores; Peptide Fragments; Prognosis; Shock, Septic; Simendan; Troponin I; United Kingdom | 2019 |
Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery.
Topics: Aged; Biomarkers; Cardiopulmonary Bypass; Cardiotonic Agents; Chi-Square Distribution; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Diseases; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Pyridazines; Risk Assessment; Risk Factors; Russia; Simendan; Stroke Volume; Treatment Outcome; Troponin I; Ventricular Function, Left | 2011 |
The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
Topics: Adrenergic beta-Agonists; Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Administration Schedule; Drug Therapy, Combination; Elective Surgical Procedures; Female; Heart Diseases; Humans; Hydrazones; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2007 |
5 other study(ies) available for simendan and Cardiac Diseases
| Article | Year |
|---|---|
Comparison of dobutamine and levosimendan for treatment of sepsis-induced cardiac dysfunction: A protocol for systematic review and meta-analysis.
Topics: Dobutamine; Heart Diseases; Humans; Meta-Analysis as Topic; Sepsis; Simendan; Systematic Reviews as Topic | 2022 |
Proarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study.
Topics: Cardiotonic Agents; Heart Diseases; Humans; Hydrazones; Hypothermia; Isoproterenol; Milrinone; Myocytes, Cardiac; Pyridazines; Simendan | 2023 |
Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Clinical Decision-Making; Congresses as Topic; Consensus; Evidence-Based Medicine; Heart Diseases; Humans; Patient Selection; Perioperative Care; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Treatment Outcome | 2018 |
Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Topics: Animals; Antibiotics, Antineoplastic; Calcium Signaling; Calcium-Binding Proteins; Cardiotoxicity; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Male; Mammary Neoplasms, Experimental; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats, Wistar; Simendan; Time Factors | 2020 |
Levosimendan infusion improves cardiac output but not blood pressure in a rodent model of severe metoprolol toxicity.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Heart; Heart Diseases; Hydrazones; Male; Metoprolol; Pyridazines; Rats; Rats, Wistar; Simendan; Vasodilator Agents | 2012 |